Plain-English translation of NCT07558850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called anti-CD19/BCMA universal CAR-T cell injection (KN3601) for autoimmune diseases that have not responded to standard treatments. The medication works by modifying immune cells to help stop the body's immune system from attacking its own tissues. Researchers want to see if this approach is safe and effective for people with rheumatoid arthritis, lupus, dermatomyositis, or systemic sclerosis.
Many people with severe autoimmune diseases don't get better with standard medications, leaving them with ongoing pain, inflammation, and disability. This trial exists to test whether this new cellular therapy could help patients who have exhausted other treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive a chemotherapy regimen to prepare your body, followed by an infusion of the modified immune cells. The trial involves multiple clinic visits for blood tests, imaging, and health monitoring to track how your body responds to the treatment. The study is designed to test different dose levels of the medication, starting with lower doses and increasing as safety is confirmed.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China